PerkinElmer, Inc. (NYSE:PKI) Files An 8-K Completion of Acquisition or Disposition of AssetsItem 2.01.
On December20, 2017, PerkinElmer, Inc. (the “Company”) filed a Current Report on Form 8-K reporting that on December19, 2017 the Company, through its indirect, wholly owned subsidiary, PerkinElmer Germany Diagnostics GmbH, completed its acquisition of EUROIMMUN Medizinische Labordiagnostika AG (“EUROIMMUN”) such that EUROIMMUN became an indirect subsidiary of the Company.
This Current Report on Form 8-K/A amends the original Form 8-K to provide the historical financial statements of EUROIMMUN required under Item 2.01(a) and the pro forma financial information required under Item 2.01(b).
| Item 2.01. | Financial Statements and Exhibits. |
(a) Financial Statements of Businesses Acquired
The audited consolidated financial statements of EUROIMMUN as of and for the year ended December31, 2016 are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and are incorporated by reference herein. The consent of EUROIMMUN’s independent auditors is attached hereto as Exhibit 23.1.
(b) Pro Forma Financial Information
The unaudited pro forma condensed combined financial information of the Company and EUROIMMUN for the year ended January1, 2017 are included as Exhibit 99.2 to this Current Report on Form 8-K/A and are incorporated by reference herein.
(d) Exhibits
| * | The exhibits and schedules to this agreement have been omitted from this filing to Item601(b)(2) of RegulationS-K. The registrant agrees to furnish copies of any such exhibits or schedules to the SEC upon request. |
PERKINELMER INC ExhibitEX-23.1 2 d495186dex231.htm EXHIBIT 23.1 Exhibit 23.1 Exhibit 23.1 CONSENT OF INDEPENDENT AUDITOR We consent to the incorporation by reference in the Registration Statements of PerkinElmer,…To view the full exhibit click here
About PerkinElmer, Inc. (NYSE:PKI)
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental and laboratory markets. The Company’s operating segments include Human Health, Environmental Health and Corporate. The Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier. Within its Human Health segment, the Company serves the diagnostics and research markets. It provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. The Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, secure surroundings and energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. The Company markets its products and services in over 150 countries.